Grothey, Axel

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 3,421

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 2,895

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology

Genetic factors in colorectal cancerColorectal Cancer Treatments and Studies

Cited by 1,623

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 1,491

Duration of adjuvant chemotherapy for stage III colon cancer

Grothey, A., Sobrero, A. F., Shields, A. F., Yoshino, T., Paul, J., Taieb, J., Souglakos, J., Shi, Q., Kerr, R., Labianca, R., et al. (2018) · New England Journal of Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 1,092

Ramucirumab versus Placebo in Combination with Second-Line FOLFIRI in Patients with Metastatic Colorectal Carcinoma That Progressed during or after First-Line Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine (RAISE): A Randomised, Double-Blind, Multicentre, Phase 3 Study

Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesAngiogenesis and VEGF in Cancer

Cited by 952

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology

Statistical Methods in Clinical TrialsColorectal Cancer Treatments and Studies

Cited by 713

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T. W., Ismail, F., Tan, I. B., Yeh, K.-H., et al. (2018) · Annals of Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 573

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Tabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2021) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 569

A Home-Based Exercise Program to Improve Function, Fatigue, and Sleep Quality in Patients With Stage IV Lung and Colorectal Cancer: A Randomized Controlled Trial

Cheville, A. L., Kollasch, J., Vandenberg, J., Shen, T., Grothey, A., Gamble, G., & Basford, J. R. (2013) · Journal of Pain and Symptom Management

Cancer survivorship and careIntensive Care Unit Cognitive Disorders

Cited by 299

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Van Cutsem, E., Huijberts, S., Grothey, A., Yaeger, R., Cuyle, P.-J., Elez, E., Fakih, M., Montagut, C., Peeters, M., Yoshino, T., et al. (2019) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 224

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 178

Napabucasin: an update on the first-in-class cancer stemness inhibitor

Hubbard, J. M., & Grothey, A. (2017) · Drugs

Cancer Cells and MetastasisPI3K/AKT/mTOR signaling in cancer

Cited by 157

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

Van Cutsem, E., Martinelli, E., Cascinu, S., Sobrero, A., Banzi, M., Seitz, J.-F., Barone, C., Ychou, M., Peeters, M., Brenner, B., et al. (2019) · The Oncologist

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 142

A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis

Jordan, K., Hinke, A., Grothey, A., Voigt, W., Arnold, D., Wolf, H.-H., & Schmoll, H.-J. (2007) · Supportive Care in Cancer

Nausea and vomiting managementPregnancy and Medication Impact

Cited by 93

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Mettu, N. B., Twohy, E., Ou, F.-S., Halfdanarson, T. R., Lenz, H. J., Breakstone, R., Boland, P. M., Crysler, O., Wu, C., Grothey, A., et al. (2019) · Annals of Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 72

A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.

Siena, S., Di Bartolomeo, M., Raghav, K. P. S., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., et al. (2020) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 54

Clinical and Functional Characterization of Atypical KRAS / NRAS Mutations in Metastatic Colorectal Cancer

Loree, J. M., Wang, Y., Syed, M. A., Sorokin, A. V., Coker, O., Xiu, J., Weinberg, B. A., Vanderwalde, A. M., Tesfaye, A., Raymond, V. M., et al. (2021) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesProtein Kinase Regulation and GTPase Signaling

Cited by 43

Broad Detection of Alterations Predicted to Confer Lack of Benefit from EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer

Rankin, A., Klempner, S. J., Erlich, R., Sun, J. X., Grothey, A., Fakih, M., George, T. J., Lee, J., Ross, J. S., Stephens, P. J., et al. (2016) · The Oncologist

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 40

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

Siena, S., Raghav, K., Masuishi, T., Yamaguchi, K., Nishina, T., Elez, E., Rodriguez, J., Chau, I., Di Bartolomeo, M., Kawakami, H., et al. (2024) · Nature Communications

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 30

O-3 Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies

Salem, M., El-Refai, S., Sha, W., Grothey, A., Puccini, A., George, T., Hwang, J., Kadakia, K., Musselwhite, L., Van Cutsem, E., et al. (2021) · Annals of Oncology

Cancer Genomics and DiagnosticsGastrointestinal Tumor Research and Treatment

Cited by 26

Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial

Teufel, M., Schwenke, S., Seidel, H., Beckmann, G., Reischl, J., Vonk, R., Lenz, H.-J., Tabernero, J., Siena, S., Grothey, A., et al. (2015) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 26